AlphaRx, Venturepharm sign supply agreement for ARX1088's API

AlphaRx Inc. (OTCBB: ALRX) announced today that it has signed an agreement that provides long-term supply of the active pharmaceutical ingredient (API) for ARX1088, an orally active interferon inducer intended for the adjunctive treatment of Hepatitis in China and other emerging markets. Under the agreement, Venturepharm will be the primary supplier of AlphaRx's worldwide requirements for the compound.

Hepatitis is a potentially life-threatening liver infection caused by the hepatitis virus. It is a major global health problem and the most serious type of viral hepatitis. It can cause chronic liver disease and puts people at high risk of death from cirrhosis of the liver and liver cancer. Worldwide, an estimated two billion people have been infected with the hepatitis virus, and more than 350 million have chronic (long-term) liver infections. There are no satisfactory treatment options currently available for Hepatitis.

"This contract manufacturing relationship marks another important step in our strategic plan for the development of ARX1088. We are currently focused on commercializing ARX1088 in China and South America," said Ruby Hui, President of AlphaRx China Operations. "The supply agreement provides us with an uninterrupted supply of product to complete our planned clinical trials in China. It also assures that there will not be a gap between the supply of clinical materials and the supply of product for commercialization, the agreement potentially eliminates manufacturing delays that could affect bringing ARX1088 to market."

SOURCE AlphaRx Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Semaglutide reduces urine albumin-to-creatinine ratio in overweight chronic kidney disease patients